Nugent S, Castellano CA, Goffaux P, Whittingstall K, Lepage M, Paquet N, Bocti C, Fulop T, Cunnane SC. Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. Am J Physiol Endocrinol Metab 306: E1315-E1321, 2014. First published April 15, 2014 ; doi:10.1152/ajpendo.00067.2014.-Several studies have suggested that glucose hypometabolism may be present in specific brain regions in cognitively normal older adults and could contribute to the risk of subsequent cognitive decline. However, certain methodological shortcomings, including a lack of partial volume effect (PVE) correction or insufficient cognitive testing, confound the interpretation of most studies on this topic. We combined [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) and magnetic resonance (MR) imaging to quantify cerebral metabolic rate of glucose (CMRg) as well as cortical volume and thickness in 43 anatomically defined brain regions from a group of cognitively normal younger (25 Ϯ 3 yr old; n ϭ 25) and older adults (71 Ϯ 9 yr old; n ϭ 31). After correcting for PVE, we observed 11-17% lower CMRg in three specific brain regions of the older group: the superior frontal cortex, the caudal middle frontal cortex, and the caudate (P Յ 0.01 false discovery rate-corrected). In the older group, cortical volumes and cortical thickness were 13-33 and 7-18% lower, respectively, in multiple brain regions (P Յ 0.01 FDR correction). There were no differences in CMRg between individuals who were or were not prescribed antihypertensive medication. There were no significant correlations between CMRg and cognitive performance or metabolic parameters measured in fasting plasma. We conclude that highly localized glucose hypometabolism and widespread cortical thinning and atrophy can be present in older adults who are cognitively normal, as assessed using age-normed neuropsychological testing measures.
aging; positron emission tomography; cerebral glucose metabolism; cortical volume; cortical thickness GLUCOSE UPTAKE IN THE BRAIN is determined by synaptic function and neuronal activity (35, 41) . Thus, cortical gray matter areas have higher glucose uptake because they have higher neuronal density than white matter areas (2) . In Alzheimer's disease, the parietal and temporal cortex exhibit lower glucose uptake that is proportional to the severity of the disease (7, 26) . A common interpretation of this regionalized decline in brain glucose uptake is that it is a consequence of neuronal deterioration and death (6) . Although neuronal death would certainly reduce glucose consumption, several studies suggest that regional brain glucose hypometabolism can be present in those at genetic or familial risk of Alzheimer's disease who do not yet show clinical evidence of cognitive decline (27, 32, 34) and as early as in young adulthood (33) . The implication is that regional brain glucose hypometabolism may not be simply the result of neuropathology and neuronal death but could also be contributing to the risk of subsequent aging-related cognitive decline and Alzheimer's disease (9) .
Aging is the main risk factor for Alzheimer's disease, so it is important to determine whether brain glucose hypometabolism could be present before or only after the onset of agingassociated cognitive decline. Most reports on brain glucose metabolism in older adults have one or more of the following limitations that make it difficult to be certain whether regional brain glucose hypometabolism was present in individuals who do not present with cognitive decline (9): 1) brain glucose uptake was not corrected for partial volume effects (PVE) in positron emission tomography (PET) with [
18 F]flurodeoxyglucose ([ 18 F]FDG); 2) brain glucose uptake was not quantified, i.e., the cerebral metabolic rate of glucose (CMRg; mol·100 g Ϫ1 ·min Ϫ1 ) of the global or regional differences in glucose uptake was not shown; 3) cognitive evaluation was insufficient in order to be certain that all of the older participants were definitely cognitively normal for their age; or 4) whether the older participants were medicated for conditions that may affect brain glucose metabolism and their risk of cognitive decline was unclear (25) .
PVE is an important potential confounder because estimates of the true radioactivity of PET radiotracers in small brain regions are influenced by the radioactivity in adjacent regions (14, 31) . PVE is particularly marked when cortical atrophy is present, which is a common feature of the aging brain (1). Thus, accurate quantification of CMRg in the aging brain requires PVE correction (9, 36, 48) . Three PET studies in older adults reported that no age-related differences in brain glucose metabolism were present after correction for PVE (10, 22, 48) . Two other studies found that after PVE correction, brain glucose hypometabolism was indeed present in the frontal cortex alone (24) or principally in the frontal cortex but also in specific temporal and subcortical regions (28) .
Of the aforementioned studies, only two of them (22, 24) also administered an in-depth battery of cognitive tests sufficient to fully evaluate the cognitive status of their young and older participants undergoing [ 18 F]FDG-PET. Others did not report having performed any assessment of cognition (10) or administered only the mini-mental state examination [MMSE; (19) ], which provides only a rudimentary evaluation of global cognitive status (28, 48) . If regional brain glucose hypometabolism is truly a feature of normal aging in cognitively healthy adults, it seems most likely to be present in the frontal cortex (24) , but the actual magnitude of this deficit remains unclear. The inclusion of a measure of the actual magnitude of glucose hypometabolism would be useful because it would provide a potential therapeutic target for treatment using alternative brain fuels that could potentially compensate for brain glucose hypometabolism (9) . Therefore, the primary aim of the present study was to quantify the magnitude of regional CMRg (mol·100 g Ϫ1 ·min
Ϫ1
), including PVE correction, in young and older adults who were cognitively normal for their age. Participants were screened for normal cognition by a comprehensive battery of neurocognitive tests. Scaled age-corrected scores were compared between the two groups to determine whether cognitive deficits were present in the older participants. We are not aware of any studies in which these three attributes have been reported in a single [ 18 F]FDG-PET study during aging. Magnetic resonance (MR) images were acquired to correct for PVE but also to permit the reporting of regional brain volumes and cortical thickness. Cortical thickness declines on the order of 0.2%/yr in individuals Ͼ55 yr of age, particularly in the temporal and occipital cortex (43) . Hypertension and mild metabolic dysregulation are common in the elderly and are important risk factors for the development of Alzheimer's disease (20, 50) . Therefore, the secondary aims of the present study were to compare CMRg between older participants who were and were not taking antihypertensive medication and to determine whether there was an association between blood parameters associated with glucose metabolism and global or regional CMRg.
EXPERIMENTAL PROCEDURES
Participants. Ethical approval for this study was obtained from Centre de Santé et de Services Sociaux-Institut Universitaire de Gériatrie de Sherbrooke and Centre Hospitalier Universitaire de Sherbrooke ethics committees. All participants provided written informed consent prior to study entry. Participants were between either 18 and 30 (young adult group; n ϭ 25) or 65 and 85 yr of age (older adult group; n ϭ 31). They all underwent a prescreening visit, which included analysis of a blood sample collected after an overnight fast and completion of a medical history questionnaire. Exclusion criteria included a MMSE score of Ͻ26, smoking, diabetes, or glucose intolerance [elevated fasting plasma glucose according to World Health Organization (47) recommendations (Ն6.1 mM) or glycated hemoglobin (Hb A1c) Ն6.5%], and evidence of overt heart, liver, or renal disease and untreated hypertension, dyslipidemia, or thyroid disease. None of the young participants were medicated. Thirteen of the 31 older adult participants were taking prescription medication for hypertension (Irbesartan, Ramipril, or Telmisartan). Five had prescriptions for statins (Atorvastatin and Rosuvastatin), and five were taking a synthetic form of the thyroid hormone thyroxine (levothyroxine).
Cognitive tests. Tasks for which response time was the primary measurement or those that were highly dependent on processing speed were classified as being in the processing speed domain ( Table 2) (40) . Delayed memory was assessed using the Logical Memory II and Verbal Paired Associates II from the WMS-III (45) and delayed recall from the RCFT (40) .
MR images. For each participant, T1-weighted MR images were acquired on a 1.5 Tesla scanner (Magnetom Symphony; Siemens Medical Solutions, Erlangen, Germany). The parameters of the gradient echo sequence were repetition time/echo time Ϫ 16.00/4.68 ms, Volume and cortical thickness. Gray matter volumes and cortical thickness were determined using FreeSurfer pipeline Suite 5.0 (Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Cambridge, MA). The cortex was automatically parcellated into 43 regions of interest (ROI) that were averaged for the left and right hemispheres. Briefly, this processing included the removal of nonbrain tissue using a hybrid watershed/ surface deformation procedure (37), automated Talairach transformation, segmentation of white and gray matter (16, 17) , intensity normalization (42) , and topology correction (15, 38) . Then the surface deformation was used to form tissue boundaries (11) . Next, the cerebral cortex was parcellated using a sulcal depth-based anatomic parcellation method (13). Regional brain volumes were then normalized using intracranial volumes (46) .
PET and cerebral metabolic rate of glucose. Brain PET scans were performed on a Philips Gemini TF PET/CT scanner (Philips Medical System, Eindhoven, The Netherlands) using a dynamic list mode acquisition, with time of flight enabled, an isotropic voxel size of 2 mm 3 , field of view of 25 cm, and an axial field of 18 cm. Time frames were allocated according to 12 ϫ 10 s, 8 ϫ 30 s, 6 ϫ 4 min, and 3 ϫ 10 min for a total scan length of 60 min. After breakfast, each participant fasted for 6 -7 h before scanning, which was performed at around 3 PM. Each participant's head was positioned in the headrest and gently restrained with straps in a dark quiet environment. An indwelling venous catheter was introduced into a forearm vein that was placed in a hand warmer at 44°C (30) . A second catheter was placed in the contralateral forearm vein for the injection of 5 mCi of [ 18 F]FDG, which was infused over 20 s using an infusion pump. Blood samples were obtained at 3, 8, 16, 24, 35 , and 55 min after [ 18 F]FDG infusion. Radioactivity in plasma samples was counted in a ␥-counter (Cobra; Packard) cross-calibrated with the PET scanner.
PET images underwent a series of preprocessing steps to produce quantitative images of brain glucose uptake. First, PET images were automatically coregistered to each participant's respective MR image using a cross-modality three-dimensional image fusion tool implemented in PMOD 3.3 (PMOD Technologies, Zurich, Switzerland). Coregistered PET images were then corrected for PVE using the modified Müller-Gartner method (31), which is fully implemented in the PVElab software (http://nru.dk/downloads/software).
Quantification of CMR requires an arterial input function, which is defined as the rate of arrival of the PET tracer to the tissue of interest. Arterial input functions were determined by tracing ROIs on the internal carotid arteries with the aid of coregistered MR images, as validated previously in humans (49) . The calculated activity within the ROI was corrected to the radioactivity of the plasma samples obtained during PET image acquisition. The lumped constant used to calculate CMRg was set to 0.80 (21) . CMRg was expressed as micromoles per 100 grams per minute using the graphical Patlak model (29) . CMRg is calculated as the product of the rate constant (K) for the tracer uptake multiplied by the plasma concentration of glucose. CMRg data were averaged within each ROI defined by FreeSurfer Suite 5.0.
Plasma metabolites. All metabolites were measured using an automated clinical chemistry analyzer (Dimension Xpand Plus; Siemens Healthcare Diagnostics, Deerfield, IL). Plasma insulin was analyzed by commercial enzyme-linked immunosorbent assay (Alpco, Salem, NH) with a Victor X4 multilabel plate reader (Perkin-Elmer, Woodbridge, ON, Canada).
Data presentation and statistical analysis. Data are presented as means Ϯ SD. Levene's test was used to assess the normality of data (P Յ 0.05), and t-tests with unequal variance were employed if Levene's test was significant. Brain regions refer to gray matter only, with white matter being identified separately. Independent Student t-tests were used to compare CMRg between the young and older groups. All statistical analyses were carried out using SPSS 17.0 software (SPSS, Chicago, IL). The GLM procedure from SPSS with education introduced as a covariate was used to compare cognitive test scores of the younger and older adults. Percent difference between the two groups was expressed as ([older Ϫ young]/young ϫ 100). These comparisons underwent a P Յ 0.01 false discovery rate (FDR) correction (5) . Pearson correlations were performed to assess associations between CMRg and regional gray matter volume or cortical thickness.
RESULTS
Metabolic parameters. The older adults were 5% shorter (P ϭ 0.001) and had 4% lower plasma albumin (P ϭ 0.001), 13% higher body mass index (P ϭ 0.022), and 12% higher Hb A 1c (P Յ 0.0001) when compared with the younger participants ( Table 1) .
Cognitive battery. There were several differences between the young and older participants regarding raw cognitive test scores corrected for education (Table 2 ). To evaluate performance compared with age-matched peers and to determine whether participants in our older group presented with cognitive deficits, raw cognitive scores were corrected for age in addition to education and were presented as scaled scores. Statistical analysis of scaled scores showed no difference between the two groups in either the speed processing or executive function domains (P Ն 0.20). However, older participants scored 9 -10% higher than the young group in immediate and delay recall tasks from the RCFT (P ϭ 0.001).
CMRg. After PVE correction, whole brain gray or white matter CMRg was not significantly different between the two groups (P ϭ 0.312). FDR-corrected CMRg (P Յ 0.01) was significantly lower in the older adults in the superior frontal cortex (Ϫ12%, P ϭ 0.005), caudal middle frontal cortex (Ϫ11%, P ϭ 0.005), and caudate nucleus (Ϫ17%, P Յ 0.0001) ( Table 3 and Fig. 1) .
Cortical volume and thickness. Gray matter volume was 13-33% lower in many brain regions in the older group (all P Յ 0.01, FDR corrected; Table 4 ). In the older participants, the lateral ventricles were more than twice the volume of those in the younger adults. Cortical thickness was 7-18% lower in many brain areas in the older group (all P Յ 0.01, FDR corrected; Table 5 ).
Antihypertensive medication. There were no significant differences in regional CMRg when older adults on antihypertensive medication (n ϭ 13) were compared with older adults not on antihypertensive medication (n ϭ 18).
Metabolic parameters in blood and regional CMRg. There were no statistically significant correlations between any of the measured metabolic parameters and CMRg in any region of the brain, including Hb A 1c , which was significantly higher in the older group (Table 1) .
Cognitive function and regional CMRg. Correlations between raw cognitive test scores and CMRg were tested in the two frontal regions and caudate, which exhibited glucose hypometabolism in the older group. No significant correlations were observed between any of the regions exhibiting glucose hypometabolism and raw cognitive test scores (all P Ͼ 0.05).
DISCUSSION
The main outcome of this study was that our older group had significant regional brain glucose hypometabolism on the order 
Values are means Ϯ SD and in mol·100 g Ϫ1 ·min Ϫ1 ; n ϭ 25 young adults and 31 older adults. CMRg, cerebral metabolic rate of glucose. Difference column is (older Ϫ young)/young ϫ 100%. *Statistically significant difference between young and older adults after P Յ 0.01, false discovery rate correction for multiple comparisons. Fig. 1 . Brain regions with significantly lower glucose uptake in the older group compared with the younger group, including the superior frontal cortex (orange), caudal middle frontal cortex (red), and caudate (yellow). All results were false discovery rate corrected for multiple comparisons; P Յ 0.01. of 11-17% in gray matter of the superior frontal cortex, caudal middle frontal cortex, and caudate (Table 3 and Fig. 1 ). When cognitive status was assessed using scaled scores, the older group had similar scores to age-matched individuals and no evidence of cognitive deficit. Hence, regional brain glucose hypometabolism can be present in older individuals with no cognitive deficit. Whether this degree of glucose hypometabolism in these regions is predictive of the increased risk of Alzheimer's disease remains to be seen. In addition to demonstrating localized brain glucose hypometabolism relative to younger participants, we show that the volume of multiple brain regions was 13-33% lower and that widespread cortical thinning on the order of 7-18% was present in our older group (Tables 4 and 5 ). This suggests that individuals averaging 71 yr of age can be cognitively normal despite widespread declining gray matter volume, extensive cortical thinning, and localized glucose hypometabolism. Thus, we add to the emerging evidence that several changes are occurring in the brains of older individuals who do not present with cognitive deficit and who are considered to not be impaired when compared relative with age-matched peers (27, (32) (33) (34) . Regional cortical atrophy and cortical thinning were more widespread and were generally of a greater magnitude in the older group than was regional brain glucose hypometabolism, indirectly suggesting that cortical thinning and atrophy may be occurring before glucose hypometabolism, as has been reported in previous longitudinal studies (4, 23) . Furthermore, in regions commonly vulnerable to Alzheimer's disease pathogenesis, including the entorhinal, parahippocampal, and cingulate regions, glucose metabolism was relatively normal, and little atrophy was present. This suggests that regional brain atrophy during normal aging is distinct from that of Alzheimer's disease. Fjell et al. (18) performed a longitudinal study and found that entorhinal atrophy was significantly greater in mild cognitive impairment when compared with a cognitively normal age-matched group. Kalpouzos et al. (24) also reported that the hippocampus and posterior cingulate demonstrated the least deterioration in glucose metabolism during aging and suggested that alterations in these regions appear to reflect the separation between normal aging and Alzheimer's disease. 
Values are means Ϯ SD and in ml; n ϭ 25 young adults and 31 older adults. All data are corrected for intracranial volumes. Difference column is (older Ϫ young)/young ϫ 100%. *Statistically significant difference between young and older adults after P Յ 0.01, false discovery rate correction for multiple comparisons. 
Values are means Ϯ SD and in mm; n ϭ 25 young adults and 31 older adults. Difference column is (older Ϫ young)/young ϫ 100%. *Statistically significant difference between young and older adults after P Յ 0.01, false discovery rate correction for multiple comparisons.
The older group had normal age-corrected results on an extensive cognitive battery of tests, including the evaluation of various cognitive domains, processing speed, executive function, and memory. Indeed, the older group actually performed better than the younger group in delayed recall tasks from the RCFT after adjustment for age and education (data not shown), underlining their relatively healthy overall cognitive status. Since lower CMRg was observed in cortical areas responsible for higher cognitive functions (as opposed to primary sensory areas such as auditory, motor, and visual cortex), it is possible that glucose hypometabolism in these regions may be linked to a risk of future cognitive decline. Nevertheless, we did not observe a significant association between glucose hypometabolism in any of the three regions affected in the older group and raw cognitive test scores. Hence, the mild stage of brain glucose hypometabolism in our older participants did not appear to be linked directly to cognitive outcomes.
Global or regional CMRg was not affected by whether or not the older group was taking antihypertensive medication. Whether untreated hypertension is associated with lower CMRg remains to be established. There was also no significant association between metabolic parameters measured in the blood and CMRg in any brain region. A study by Baker et al. (3) found that greater insulin resistance was related to lower CMRg in the frontal, parietotemporal, and cingulate regions in older adults newly diagnosed as prediabetic or type 2 diabetic. However, Baker et al. (3) did not apply a PVE correction to their [
18 F]FDG-PET data. The relatively large variability in their plasma insulin values may also have permitted them to detect an inverse correlation with CMRg, a relationship that was precluded in our study by the narrow and normal range of fasting insulin found in our two groups. Hb A 1c was 12% higher in the older group but was still Ͻ6.0%, which is the suggested upper limit of normal for older nondiabetic adults (39) . Although we did not find any significant correlations between CMRg and Hb A 1c , previous studies have found that higher fasting serum glucose levels are associated with glucose hypometabolism in regions commonly affected in Alzheimer's disease (8) .
Limitations of this study include the inability to determine whether glucose hypometabolism does in fact appear before any measurable changes in regional brain volume or cortical thickness since we did not have a longitudinal design. We are presently reevaluating the group of older participants with a 2-yr followup scan that will help determine whether decreasing brain volume or cortical thickness precedes or follows decreasing CMRg. It is also possible that metabolic and structural differences in our older group were influenced by cohort effects rather than age effects per se; however, we made an effort to thoroughly define the cognitive and physical status of the groups, including an extensive cognitive battery and plasma metabolite evaluation.
In conclusion, when expressed quantitatively and with PVE and statistical correction for multiple comparisons, CMRg was 11-17% lower in the superior and caudal middle frontal cortex and in the caudate of our cohort of cognitively normal older adults. This aging-associated brain glucose hypometabolism was highly localized in contrast to cortical thinning and gray matter atrophy, both of which were widespread.
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